These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 32078672

  • 1. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, Drager D, Moore N, Liu J, Holthaus AM, Sommer JM, Ismail A, Rabinovich D, Liu Z, van der Flier A, Goodman A, Furcht C, Tie M, Carlage T, Mauldin R, Dobrowsky TM, Liu Z, Mercury O, Zhu L, Mei B, Schellenberger V, Jiang H, Pierce GF, Salas J, Peters R.
    Blood; 2020 Apr 23; 135(17):1484-1496. PubMed ID: 32078672
    [Abstract] [Full Text] [Related]

  • 2. Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.
    Fuller JR, Knockenhauer KE, Leksa NC, Peters RT, Batchelor JD.
    Blood; 2021 May 27; 137(21):2970-2980. PubMed ID: 33569592
    [Abstract] [Full Text] [Related]

  • 3. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
    Demers M, Aleman MM, Kistanova E, Peters R, Salas J, Seth Chhabra E.
    J Thromb Haemost; 2022 Jul 27; 20(7):1674-1683. PubMed ID: 35466511
    [Abstract] [Full Text] [Related]

  • 4. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
    Konkle BA, Shapiro AD, Quon DV, Staber JM, Kulkarni R, Ragni MV, Chhabra ES, Poloskey S, Rice K, Katragadda S, Fruebis J, Benson CC.
    N Engl J Med; 2020 Sep 10; 383(11):1018-1027. PubMed ID: 32905674
    [Abstract] [Full Text] [Related]

  • 5. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.
    J Thromb Haemost; 2014 Nov 10; 12(11):1788-800. PubMed ID: 25196897
    [Abstract] [Full Text] [Related]

  • 6. A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.
    Yee A, Gildersleeve RD, Gu S, Kretz CA, McGee BM, Carr KM, Pipe SW, Ginsburg D.
    Blood; 2014 Jul 17; 124(3):445-52. PubMed ID: 24850761
    [Abstract] [Full Text] [Related]

  • 7. FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.
    van der Flier A, Liu Z, Tan S, Chen K, Drager D, Liu T, Patarroyo-White S, Jiang H, Light DR.
    PLoS One; 2015 Jul 17; 10(4):e0124930. PubMed ID: 25905473
    [Abstract] [Full Text] [Related]

  • 8. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
    Miners AH, Krishnan S, Pasi KJ.
    J Thromb Haemost; 2016 Nov 17; 14(11):2141-2147. PubMed ID: 27510890
    [Abstract] [Full Text] [Related]

  • 9. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
    Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D.
    Blood; 2016 Oct 20; 128(16):2007-2016. PubMed ID: 27587878
    [Abstract] [Full Text] [Related]

  • 10. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
    Vargas Christensen I, Loftager M, Rode F, Mørck Nielsen H, Kreilgaard M, Larsen MS.
    J Thromb Haemost; 2019 Jun 20; 17(6):964-974. PubMed ID: 30924607
    [Abstract] [Full Text] [Related]

  • 11. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
    Grancha S, Ortiz AM, Marañón C, Hampel K, Moret A, Zimmermann B, Jorquera JI, Aznar JA.
    Haemophilia; 2012 Nov 20; 18(6):982-9. PubMed ID: 22646163
    [Abstract] [Full Text] [Related]

  • 12. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
    Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF.
    Blood; 2012 Mar 29; 119(13):3031-7. PubMed ID: 22223821
    [Abstract] [Full Text] [Related]

  • 13. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA.
    Expert Rev Hematol; 2023 Mar 29; 16(8):567-573. PubMed ID: 37289594
    [Abstract] [Full Text] [Related]

  • 14. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
    Elsheikh E, Lavin M, Heck LA, Larkin N, Mullaney B, Doherty D, Kennedy M, Keenan C, Guest T, O'Mahony B, Fazavana J, Fallon PG, Preston RJS, Gormley J, Ryan K, O'Connell NM, Singleton E, Byrne M, McGowan M, Roche S, Doyle M, Crowley MP, O'Shea SI, Reipert BM, Johnsen JM, Pipe SW, Di Paola J, Turecek PL, O'Donnell JS, iPATH study group.
    J Thromb Haemost; 2023 May 29; 21(5):1123-1134. PubMed ID: 36775768
    [Abstract] [Full Text] [Related]

  • 15. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
    Shi Q, Schroeder JA, Kuether EL, Montgomery RR.
    J Thromb Haemost; 2015 Jul 29; 13(7):1301-9. PubMed ID: 25955153
    [Abstract] [Full Text] [Related]

  • 16. High-affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats.
    Øie CI, Roepstorff K, Behrens C, Bøggild Kristensen J, Karpf DM, Bolt G, Gudme CN, Kjalke M, Smedsrød B, Appa RS.
    J Thromb Haemost; 2016 Sep 29; 14(9):1803-13. PubMed ID: 27378673
    [Abstract] [Full Text] [Related]

  • 17. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
    Lalezari S, Martinowitz U, Windyga J, Enriquez MM, Delesen H, Schwartz L, Scharrer I.
    Haemophilia; 2014 Jan 29; 20(1):e15-22. PubMed ID: 24252058
    [Abstract] [Full Text] [Related]

  • 18. Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII.
    Chia J, Pestel S, Glauser I, Emmrich K, Hardy MP, Mischnik M, Raquet E, Tomasetig V, Claar P, Zalewski A, Bass GT, Turnbull V, Chen CG, Wilson MJ, Panousis C, Weimer T, Andrews A, Verhagen AM, Dower SK.
    J Thromb Haemost; 2021 Nov 29; 19(11):2710-2725. PubMed ID: 34333849
    [Abstract] [Full Text] [Related]

  • 19. Physiological Roles of the von Willebrand Factor-Factor VIII Interaction.
    Kiouptsi K, Reinhardt C.
    Subcell Biochem; 2020 Nov 29; 94():437-464. PubMed ID: 32189311
    [Abstract] [Full Text] [Related]

  • 20. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
    Cao W, Trask AR, Bignotti AI, George LA, Doshi BS, Sabatino DE, Yada N, Zheng L, Camire RM, Zheng XL.
    J Thromb Haemost; 2023 Dec 29; 21(12):3477-3489. PubMed ID: 37726033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.